Early Clinical Predictors of Ulcerative Progression in Necrobiosis Lipoidica: A Comprehensive Review of Warning Signs, Risk Factors, and Long-Term Outcomes
Background: Necrobiosis lipoidica (NL) is a chronic granulomatous dermatosis of the lower legs. Its most serious complication is ulceration, which brings pain and prolonged wound care and, rarely, cutaneous malignancy. Whether ulceration can be anticipated in nonulcerated disease has not been critically examined. Objective: To determine whether early clinical manifestations or patient- and lesion-related factors identify patients with nonulcerated NL at increased risk of ulceration, and to appraise evidence on healing, recurrence and long-term outcomes. Evidence synthesis: Europe PMC (including MEDLINE) was searched from inception to 25 October 2026 (895 NL records; 499 unique records screened across 16 topic strategies), supplemented by ClinicalTrials.gov, full texts and citation chasing. Candidate predictors were classified as longitudinal predictors, cross-sectional associations, activity markers, indicators of established breakdown, or theoretical factors. Key findings: Ulceration affected 12.7% to about 35% of patients in referral and multicentre cohorts, but no study followed nonulcerated patients to measure incident ulceration, and no feature qualified as a longitudinal predictor. In the largest comparison (83 ulcerated vs 233 nonulcerated patients), ulcerated disease was more often painful (52% vs 36%), larger (median 7 vs 5 cm) and associated with lesional malignancy (7% vs 0%), without differences in venous insufficiency or transcutaneous oxygen; temporal order was not established. The diabetes association was inconsistent (16.7% vs 7.3%, P = .03, in one cohort; 30% vs 28%, P = .79, in another), and no analysis was adjusted. Male sex was overrepresented among ulcerated patients in German cohorts. Atrophy, telangiectasia, trauma, smoking, glycaemic control and microvascular change remain unvalidated or theoretical. Evidence on healing comes almost entirely from case reports and small uncontrolled series. Recurrence after treatment withdrawal is often described but has not been quantified. Malignancy, mostly squamous cell carcinoma, arose in 6 of 328 patients in one referral cohort, all within ulcerated lesions. No intervention has been shown to prevent first ulceration. Conclusion: There are no validated early predictors of ulceration in NL. It is reasonable to document painful, enlarging or crusted lesions carefully, avoid trauma, assess vascular status and biopsy atypical or nonhealing ulcers, but evidence-based risk stratification will require prospective inception cohorts.
Authors
- Saud Abdullah Ali Alsharif
Publication Details
- Journal
- HAL
- Published
- 2026-11-14
- DOI
- https://doi.org/10.59324/jcpmr.2026.2(6).09
- Primary Topic
- Skin Diseases and Diabetes
- Type
- article
- Field-Weighted Citation Impact
- 0.00